
|Videos|February 11, 2014
Toxicities Associated With Immunotherapies
Author(s)Harriet Kluger, MD
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the toxicities associated with immunotherapies.
Advertisement
Clinical Pearls
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the toxicities associated with immunotherapies.
- Toxicities associated with immunotherapies are completely different than what oncologists are accustomed to
- Immunotherapies are not necessarily less toxic than chemotherapies
- Pneumonitis and colitis are life-threatening
- Occasionally, toxicities associated with immunotherapies are difficult to recognize
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5










































